论文部分内容阅读
在欧洲,安搏律定(Aprindjne)被广泛胜于治疗室性和室上性心律失常,以及传统抗心律失常药无效病例。本文报告七例使用本药的经验。病人选择:(1)经两种以上传统药物无效的复发性室性心动过速(VT);(2)对传统药物有效,但无口服剂型或不能耐受者(如利多卡因、溴苄胺)。本组七例顽固性VT系冠心病监护室或用动态EKG监测患者。安搏律定静脉给药,开始用25毫克,每五分钟增加剂量,直至总
Aprindjne is widely prevalent in Europe for the treatment of ventricular and supraventricular arrhythmias, as well as for the failure of traditional antiarrhythmic drugs. This article reports seven cases of the drug’s experience. Patient Choice: (1) Recurrent ventricular tachycardia (VT) that is ineffective with more than two traditional medications; (2) is effective on traditional medicines but not in oral dosage forms or intolerant individuals (eg, lidocaine, amine). The group of seven cases of intractable VT Department of coronary heart disease monitoring or monitoring of patients with dynamic EKG. Ambroxule given intravenously, start with 25 mg every five minutes to increase the dose until the total